222 related articles for article (PubMed ID: 33207105)
1. Azacitidine and Venetoclax in AML.
Moore JW; Pelcovits A; Reagan JL
N Engl J Med; 2020 Nov; 383(21):2088. PubMed ID: 33207105
[No Abstract] [Full Text] [Related]
2. Azacitidine and Venetoclax in AML.
Lucijanic M
N Engl J Med; 2020 Nov; 383(21):2087-2088. PubMed ID: 33207104
[No Abstract] [Full Text] [Related]
3. Azacitidine and Venetoclax in AML.
Chitikela S; Kumar L; Sahoo RK
N Engl J Med; 2020 Nov; 383(21):2087. PubMed ID: 33207103
[No Abstract] [Full Text] [Related]
4. Azacitidine and Venetoclax in AML. Reply.
DiNardo CD; Wang J; Pratz KW
N Engl J Med; 2020 Nov; 383(21):2088-2089. PubMed ID: 33207106
[No Abstract] [Full Text] [Related]
5. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
[No Abstract] [Full Text] [Related]
6. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
[No Abstract] [Full Text] [Related]
7. Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Xia L; Tian W; Zhao Y; Jiang L; Qian W; Jiang L; Ge L; Li J; Jin F; Yang M
Signal Transduct Target Ther; 2023 May; 8(1):176. PubMed ID: 37130896
[No Abstract] [Full Text] [Related]
8. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
[No Abstract] [Full Text] [Related]
9. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
[TBL] [Abstract][Full Text] [Related]
10. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Pratz KW; DiNardo CD; Selleslag D; Li J; Yamamoto K; Konopleva M; Stevens D; Kantarjian H; Traina F; Venditti A; Mayer J; Montez M; Jin H; Duan Y; Brackman D; Zha J; Potluri J; Werner M; Jonas BA
Am J Hematol; 2022 Nov; 97(11):E416-E419. PubMed ID: 36054316
[No Abstract] [Full Text] [Related]
11. Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.
Niswander LM; Chung P; Diorio C; Tasian SK
Haematologica; 2023 Nov; 108(11):3142-3147. PubMed ID: 37021525
[No Abstract] [Full Text] [Related]
12. Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
Liu Y; Zhu L; Lv Z; Mao L; Hu C; Wang J; Zhou Y; Jin J; Meng H; You L
Br J Haematol; 2023 Jun; 201(5):995-999. PubMed ID: 36999439
[No Abstract] [Full Text] [Related]
13. Azacitidine and venetoclax for post-transplant relapse in a case of CBFA2T3/GLIS2 childhood acute myeloid leukaemia.
Mishra AK; Mullanfiroze K; Chiesa R; Vora A
Pediatr Blood Cancer; 2021 Nov; 68(11):e29221. PubMed ID: 34260140
[No Abstract] [Full Text] [Related]
14. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
Lou Y; Shao L; Mao L; Lu Y; Ma Y; Fan C; Jiang H; Li J; Jin J
Leuk Res; 2020 Apr; 91():106317. PubMed ID: 32092584
[No Abstract] [Full Text] [Related]
15. Toward an improved understanding of hypomethylating agent and venetoclax therapies.
DiNardo CD
Am J Hematol; 2024 Feb; 99(2):152-154. PubMed ID: 38102772
[No Abstract] [Full Text] [Related]
16. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
Wang A; Fang M; Jiang H; Wang D; Zhang X; Tang B; Zhu X; Hu W; Liu X
Biomed Pharmacother; 2022 Sep; 153():113527. PubMed ID: 36076608
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax in AML: Where We Are and Where We Are Headed.
Pollyea DA
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S25-S26. PubMed ID: 32862856
[TBL] [Abstract][Full Text] [Related]
18. Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
Bouligny IM; Murray G; Ho T; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
Leuk Res; 2023 Nov; 134():107370. PubMed ID: 37659346
[No Abstract] [Full Text] [Related]
19. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
Jonas BA; DiNardo C; Fracchiolla N; Pristupa A; Ishizawa K; Jin J; Konopleva M; Ofran Y; Montesinos P; Kovacsovics T; Jang JH; Kantarjian H; Duan Y; Potluri J; Werner M; Pratz KW
Am J Hematol; 2022 Nov; 97(11):E422-E425. PubMed ID: 36053878
[No Abstract] [Full Text] [Related]
20. An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.
Pleyer L; Sekeres MA
Lancet Haematol; 2022 Oct; 9(10):e714-e716. PubMed ID: 36063831
[No Abstract] [Full Text] [Related]
[Next] [New Search]
